CortControl Granted U.S. Patent for Vaccine Immuno-Enhancement Treatment for At-Risk Global Populations

Glutrasol VE provides a real-time solution in the fight against global health crises

"Glutrasol VE is projected to impact literally millions of people in developing countries" - CortControl CEO and Co-Founder, Jim Daniels (Photo: iStock)

???pagination.previous??? ???pagination.next???

PORTLAND, Ore.--()--CortControl, LLC has announced that it has been granted a United States Patent for its vaccine immuno-enhancement food. The patent is the second received within the last six months by the medical foods formulation company.

CortControl’s Glutrasol™ VE will be clinically tested to enhance vaccine efficacy by boosting the patient’s immune system. Glutrasol VE is administered before, during, or after vaccination to increase antibody production.

CortControl is the sister company to Ramaekers Nutrition, which develops patented natural veterinary products to educate immune cells and enhance their function. CortControl is leveraging 40 years of studies and science developed by Ramaekers Nutrition. Glutrasol VE applies successful formulation experience from animal testing to the human arena.

“We are very excited about the potential benefits. Glutrasol VE is projected to impact literally millions of people in developing countries,” says CortControl CEO, Jim Daniels.

In numerous livestock vaccination studies, Glutrasol VE was found to increase a subject’s antibody titer by 4 to 5 times. Antibody titer numbers relate to the amount and type of antibodies in a subject’s blood, and quantify the strength of the body’s immune response. “The higher the antibody titer number, the healthier the immune response,” continues Daniels. “This is key when vaccinating at-risk populations with compromised immune systems due to poor nutrition, contaminated water, or other systemic factors. This is actually a really BIG deal for global health.”

Treatment offers two distinct benefits for global healthcare organizations and patients. First, Glutrasol VE is a medical food so is easy to administer, non-invasive and ingested just like other foods. Second, the positive immuno-enhancement effects last well beyond the unsupported vaccination timeline. Protection lasts longer, effectively maximizing medical teams’ resources.

For pharmaceutical companies and others interested in partnering with CortControl, an enormous opportunity exists. By increasing the efficacy of vaccine protocols, the cost of administering vaccines goes down and efficacy goes up. This bodes well for pharmaceutical companies wanting to boost brand recognition and profitability of their products. Further, for those involved in the logistics of vaccine delivery, the product is stable for long periods at relatively high, sustained temperatures.

In addition to vaccine immuno-enhancement and infertility enhancement foods, CortControl has more patent applications underway. The basic strategy remains the same: increase immune function to improve treatment efficacy.

About CortControl

CortControl develops market-ready, patent-protected medical foods for manufacture and distribution. CortControl’s Glutrasol™ family of products, when combined with other specific medical protocols, works to boost immune function and dramatically improve outcomes. CortControl is committed to advancing global health by sharing emerging technologies with donors, tech researchers, manufacturers and delivery organizations. Learn more at http://www.cortcontrol.com/vaccine-enhancement.

Social Media:

LINKEDIN: https://www.linkedin.com/company/cortcontrol

TWITTER: https://twitter.com/CortControl

FACEBOOK: https://www.facebook.com/CortControl/

Contacts

Cox Marketing Group, Inc.
Laura Cox, 503-803-2304
laura@coxmktg.com

Release Summary

CortControl, LLC has been granted a U.S. patent for its vaccine immuno-enhancement medical food formulation which is projected to positively impact at-risk populations in developing countries.

Contacts

Cox Marketing Group, Inc.
Laura Cox, 503-803-2304
laura@coxmktg.com